JP2022533011A5 - - Google Patents

Info

Publication number
JP2022533011A5
JP2022533011A5 JP2021564303A JP2021564303A JP2022533011A5 JP 2022533011 A5 JP2022533011 A5 JP 2022533011A5 JP 2021564303 A JP2021564303 A JP 2021564303A JP 2021564303 A JP2021564303 A JP 2021564303A JP 2022533011 A5 JP2022533011 A5 JP 2022533011A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cognitive impairment
gnrh
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021564303A
Other languages
English (en)
Japanese (ja)
Other versions
JP7779739B2 (ja
JP2022533011A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/061943 external-priority patent/WO2020221821A1/en
Publication of JP2022533011A publication Critical patent/JP2022533011A/ja
Publication of JP2022533011A5 publication Critical patent/JP2022533011A5/ja
Application granted granted Critical
Publication of JP7779739B2 publication Critical patent/JP7779739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021564303A 2019-04-30 2020-04-29 認知障害を処置するためのパルス状gnrh投与 Active JP7779739B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305550.6 2019-04-30
EP19305550 2019-04-30
PCT/EP2020/061943 WO2020221821A1 (en) 2019-04-30 2020-04-29 Pulsative gnrh administration for treating cognitive disorders

Publications (3)

Publication Number Publication Date
JP2022533011A JP2022533011A (ja) 2022-07-21
JP2022533011A5 true JP2022533011A5 (cg-RX-API-DMAC7.html) 2023-05-11
JP7779739B2 JP7779739B2 (ja) 2025-12-03

Family

ID=66625872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564303A Active JP7779739B2 (ja) 2019-04-30 2020-04-29 認知障害を処置するためのパルス状gnrh投与

Country Status (6)

Country Link
US (1) US20220202895A1 (cg-RX-API-DMAC7.html)
EP (1) EP3962494B1 (cg-RX-API-DMAC7.html)
JP (1) JP7779739B2 (cg-RX-API-DMAC7.html)
DK (1) DK3962494T3 (cg-RX-API-DMAC7.html)
ES (1) ES3067563T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020221821A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022136417A1 (en) 2020-12-22 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Pulsative gnrh administration for treating food intake related disorders
AU2023332041A1 (en) 2022-09-02 2025-02-20 Leibniz-Institut Für Immuntherapie (Lit) THERAPEUTIC USE OF THE miR155 SNP rs377265631

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158683B1 (de) 1984-04-14 1988-10-05 Ferring Biotechnik GmbH Vorrichtung zum intermittierenden Applizieren flüssiger Arzneimittel
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5013293A (en) 1987-05-28 1991-05-07 Drug Delivery Systems Inc. Pulsating transdermal drug delivery system
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
WO2007041386A2 (en) 2005-09-30 2007-04-12 Vyteris, Inc. Pulsatile delivery of gonadotropin-releasing hormone from a pre-loaded integrated electrotransport patch
WO2014110549A1 (en) * 2013-01-14 2014-07-17 The General Hospital Corporation Methods and assays relating to rnf216
WO2014179139A2 (en) * 2013-04-30 2014-11-06 Albert Einstein College Of Medicine Of Yeshiva University TREATMENT OF AGING EFFECTS BY GONADOTROPIN-RELEASING HORMONE, NEUROGENESIS OR BRAIN IKK-β/NF-κΒ INHIBITION
WO2017182580A1 (en) 2016-04-20 2017-10-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the diagnosis and the treatment of reproduction-related disorders and methods for contraception
CN108837143B (zh) * 2018-09-29 2022-03-01 南华大学 曲普瑞林的应用

Similar Documents

Publication Publication Date Title
CL2021001810A1 (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
JP2015038149A5 (cg-RX-API-DMAC7.html)
JP2017506624A5 (cg-RX-API-DMAC7.html)
FI3840753T3 (fi) Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio
JP2014198723A5 (cg-RX-API-DMAC7.html)
CN115666626A (zh) 一种治疗阿尔茨海默病的方法和药物
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
JP2022531251A5 (cg-RX-API-DMAC7.html)
CN115697386A (zh) 一种治疗帕金森病的方法和药物
MX390101B (es) Tratamiento medico que comprende administracion enteral de edaravona
MXPA03009849A (es) Uso de azitromicina para la fabricacion de un medicamento para el tratamiento de enfermedades inflamatorias no infecciosas.
JP2023537921A5 (cg-RX-API-DMAC7.html)
JP2017514911A5 (cg-RX-API-DMAC7.html)
JP2022551691A5 (cg-RX-API-DMAC7.html)
JP2019507786A5 (cg-RX-API-DMAC7.html)
JP2023531930A5 (cg-RX-API-DMAC7.html)
MX2022012693A (es) Composicion que comprende metilfolato.
JP2009500045A5 (cg-RX-API-DMAC7.html)
JP2020531543A (ja) アマンタジン組成物、その調製、および使用方法
EP4389218A3 (en) Composition for treating joint disease and kit containing same
JP2021530568A5 (cg-RX-API-DMAC7.html)
JP2021521227A5 (cg-RX-API-DMAC7.html)
JP2015515971A5 (cg-RX-API-DMAC7.html)
JP6869893B2 (ja) 前頭葉機能障害治療剤
CA2469702A1 (en) Darifenacin for use in the treatment of urgency induced by overactive bladder